336 related articles for article (PubMed ID: 18192922)
1. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy.
Pontrelli P; Rossini M; Infante B; Stallone G; Schena A; Loverre A; Ursi M; Verrienti R; Maiorano A; Zaza G; Ranieri E; Gesualdo L; Ditonno P; Bettocchi C; Schena FP; Grandaliano G
Transplantation; 2008 Jan; 85(1):125-34. PubMed ID: 18192922
[TBL] [Abstract][Full Text] [Related]
2. Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma.
Revelo MP; Federspiel C; Helderman H; Fogo AB
Nephrol Dial Transplant; 2005 Dec; 20(12):2812-9. PubMed ID: 16221712
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients.
Stallone G; Infante B; Schena A; Battaglia M; Ditonno P; Loverre A; Gesualdo L; Schena FP; Grandaliano G
J Am Soc Nephrol; 2005 Dec; 16(12):3755-62. PubMed ID: 16236802
[TBL] [Abstract][Full Text] [Related]
4. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
Wali RK; Weir MR
Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
[TBL] [Abstract][Full Text] [Related]
5. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
6. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
Segundo DS; Ruiz JC; Izquierdo M; Fernández-Fresnedo G; Gómez-Alamillo C; Merino R; Benito MJ; Cacho E; Rodrigo E; Palomar R; López-Hoyos M; Arias M
Transplantation; 2006 Aug; 82(4):550-7. PubMed ID: 16926600
[TBL] [Abstract][Full Text] [Related]
7. Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin.
Loverre A; Ditonno P; Crovace A; Gesualdo L; Ranieri E; Pontrelli P; Stallone G; Infante B; Schena A; Di Paolo S; Capobianco C; Ursi M; Palazzo S; Battaglia M; Selvaggi FP; Schena FP; Grandaliano G
J Am Soc Nephrol; 2004 Oct; 15(10):2675-86. PubMed ID: 15466272
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin attenuates the severity of murine adriamycin nephropathy.
Lui SL; Tsang R; Chan KW; Zhang F; Tam S; Yung S; Chan TM
Am J Nephrol; 2009; 29(4):342-52. PubMed ID: 18948688
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.
Bonegio RG; Fuhro R; Wang Z; Valeri CR; Andry C; Salant DJ; Lieberthal W
J Am Soc Nephrol; 2005 Jul; 16(7):2063-72. PubMed ID: 15917339
[TBL] [Abstract][Full Text] [Related]
10. The effect of combined rapamycin/cyclosporine on the changes in pro-fibrotic gene expression that occur during the development of allograft vasculopathy in rats, compared with cyclosporine or rapamycin in isolation.
Murphy GJ; Bicknell GR; Nicholson ML
Transpl Int; 2003 May; 16(5):347-53. PubMed ID: 12759727
[TBL] [Abstract][Full Text] [Related]
11. The influence of tubular phenotypic changes on the development of diffuse interstitial fibrosis in renal allografts.
Özdemir BH; Özdemir AA; Colak T; Sezer S; Haberal M
Transplant Proc; 2011 Mar; 43(2):527-9. PubMed ID: 21440751
[TBL] [Abstract][Full Text] [Related]
12. Progression of graft fibrosis under mammalian target of rapamycin inhibitor-based regimen.
Yilmaz M; Nart A; Sen S; Tasli F; Uslu A; Hur E; Ozkahya M; Hoscoskun C; Toz H
Nephrology (Carlton); 2010 Sep; 15(6):653-8. PubMed ID: 20883287
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of renal allograft fibrosis.
Waller JR; Nicholson ML
Br J Surg; 2001 Nov; 88(11):1429-41. PubMed ID: 11683737
[TBL] [Abstract][Full Text] [Related]
14. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
16. [Effects of hypoxia and tumor necrosis factor-alpha on production of plasminogen activator inhibitor-1 in human proximal renal tubular cells].
Torii K; Kimura H; Li X; Okada T; Imura T; Furusaki F; Ono T; Yoshida H
Rinsho Byori; 2005 Mar; 53(3):207-12. PubMed ID: 15839049
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical characterization of glomerular and tubulointerstitial infiltrates in renal transplant patients with chronic allograft dysfunction.
Divella C; Rossini M; Loverre A; Schena A; Maiorano A; Gesualdo V; Zaza G; Grandaliano G; Schena FP
Nephrol Dial Transplant; 2010 Dec; 25(12):4071-7. PubMed ID: 20595199
[TBL] [Abstract][Full Text] [Related]
18. Progression of renal allograft histology after renal transplantation in recurrent and nonrecurrent immunoglobulin A nephropathy.
Jeong HJ; Park SK; Cho YM; Kim MS; Kim YS; Choi J; Kim SI; Lim BJ
Hum Pathol; 2008 Oct; 39(10):1511-8. PubMed ID: 18620732
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of tubulointerstitial fibrosis in chronic allograft dysfunction.
Strutz F
Clin Transplant; 2009 Dec; 23 Suppl 21():26-32. PubMed ID: 19930313
[TBL] [Abstract][Full Text] [Related]
20. Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli.
Esposito C; Foschi A; Parrilla B; Cornacchia F; Fasoli G; Plati AR; De Mauri A; Mazzullo T; Scudellaro R; Dal Canton A
Transplant Proc; 2004 Apr; 36(3):695-7. PubMed ID: 15110634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
